AB-1015

Phase 1Biologic

AArsenal Biosciences, Inc.

AB-1015 is one of 3 biologic programs targeting Carcinoma, Ovarian Epithelial. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carcinoma, Ovarian EpithelialActive, not recruiting

Carcinoma, Ovarian EpithelialPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Carcinoma, Ovarian Epithelial

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Approved

1 2

Avastin

Roche

Approved

1 3

AB-1015

AArsenal Biosciences, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Carcinoma, Ovarian Epithelial

NCT05617755

Clinical

Trials by Indication[1]

Carcinoma, Ovarian Epithelial1 trial

An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer

Active, not recruiting·AArsenal Biosciences, Inc.·Phase 1·NCT05617755·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AB-1015. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB-1015 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB-1015. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arsenal Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: AArsenal Biosciences, Inc.

AB-1015

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Carcinoma, Ovarian Epithelial1 trial

References

Drug Info

Quick Facts

Related News